Return to Clinical Trials Search Results

Prospective Observational Study of Clinical Utility of Envisia Genomic Classifier in Patients with Undiagnosed Interstitial Lung Disease

Primary Objective: To evaluate the impact of Envisia on: * Treatment decision: Increase in proportion of patients prescribed anti-fibrotics in those with an Envisia UIP+ result versus their pre-Envisia plan. Secondary Objectives: To evaluate the impact of Envisia on: * Diagnosis: Increase in proportion of patients with a definitive diagnosis in those with an Envisia UIP+ result versus their pre-Envisia plan * Diagnostic procedures: Decrease in proportion of invasive procedures in those with an Envisia UIP+ result versus their pre-Envisia plan * Confidence level of diagnosis: Increase in proportion of patients with a higher confidence level in their diagnosis in those with an Envisia UIP+ result versus their pre-Envisia plan Exploratory Objectives: To evaluate the impact of Envisia in patients with undiagnosed ILD: * Descriptive analysis of all patients (Envisia UIP+ and UIP- result) * Change in therapy: Decrease in proportion of patients treated with Immunosuppressive/steroid in those with an Envisia UIP+ result where antifibrotic therapy was their pre-Envisia plan

Primary Objective: To evaluate the impact of Envisia on: * Treatment decision: Increase in proportion of patients prescribed anti-fibrotics in those with an Envisia UIP+ result versus their pre-Envisia plan. Secondary Objectives: To evaluate the impact of Envisia on: * Diagnosis: Increase in proportion of patients with a definitive diagnosis in those with an Envisia UIP+ result versus their pre-Envisia plan * Diagnostic procedures: Decrease in proportion of invasive procedures in those with an Envisia UIP+ result versus their pre-Envisia plan * Confidence level of diagnosis: Increase in proportion of patients with a higher confidence level in their diagnosis in those with an Envisia UIP+ result versus their pre-Envisia plan Exploratory Objectives: To evaluate the impact of Envisia in patients with undiagnosed ILD: * Descriptive analysis of all patients (Envisia UIP+ and UIP- result) * Change in therapy: Decrease in proportion of patients treated with Immunosuppressive/steroid in those with an Envisia UIP+ result where antifibrotic therapy was their pre-Envisia plan